SANOFI
500674Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Receipt Of Show Cause Notice From GST Authorities
Kindly refer the attachment
Sanofi India Ltd is a leading pharmaceutical company and a subsidiary of global healthcare leader Sanofi S. A. Headquartered in Mumbai, Sanofi India operates across the pharmaceutical value chain with a strong presence in manufacturing, marketing, and distribution of prescription medicines.
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Receipt Of Show Cause Notice From GST Authorities
Kindly refer the attachment
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Kindly refer the attachment
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Kindly refer the attachment
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Kindly refer the attachment.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Kindly refer the attachment
Announcement under Regulation 30 (LODR)-Newspaper Publication
Kindly refer the attachment
Announcement under Regulation 30 (LODR)-Investor Presentation
Kindly refer the attachment
Intimation Under Regulation 30(5) Of The Listing Regulations
Kindly refer the attachment
Re-Constitution Of The Committees Of The Company
Kindly refer the attachment
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Kindly refer the attachment
Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended 30Th June 2026
Kindly refer the attachment
Unaudited Financial Results For The Quarter And Half Year Ended 30Th June 2026
Kindly refer the attachment
Sanofi India Ltd
About
Sanofi India Ltd is a leading pharmaceutical company and a subsidiary of global healthcare leader Sanofi S. A. Headquartered in Mumbai, Sanofi India operates across the pharmaceutical value chain with a strong presence in manufacturing, marketing, and distribution of prescription medicines.
The company's portfolio encompasses therapeutic segments such as diabetes management, cardiovascular health, central nervous system disorders, and consumer healthcare. Sanofi India maintains a significant investment in research and development, focusing on both innovative branded formulations and legacy products.
With a pan-India reach, Sanofi India serves healthcare professionals, patients, and institutions through an extensive distribution network and established manufacturing facilities in Goa and Ankleshwar. The company is committed to improving access to essential medicines and contributing to public health through various awareness and education initiatives.
Business Model & Strategy
Sanofi India Ltd generates revenue primarily through the manufacture and sale of prescription pharmaceuticals and consumer healthcare products. Its business is anchored by strong brands like Lantus (insulin glargine), Allegra (antihistamine), Combiflam, and Amaryl. A significant portion of revenue also comes from contract manufacturing and strategic out-licensing agreements with other healthcare companies.
The company leverages Sanofi's global R&D pipeline and localizes the manufacturing of proven global products for the Indian market.
The growth strategy emphasizes therapeutic leadership in diabetes and cardiology, expansion in over-the-counter (OTC) segments, and increased focus on digital engagement with healthcare professionals. In addition, Sanofi India pursues partnerships with both public and private sectors for broader healthcare access while optimizing operational efficiency through digitization and supply chain initiatives.
Management Overview
10 MembersMr.ADITYA NARAYAN
Non-Executive - Independent Director-ChairpersonMr.Mahadev Gawade
Executive DirectorMrs.USHA THORAT
Non-Executive - Independent DirectorMr.RODOLFO HROSZ
Non-Executive - Non Independent DirectorMr.RAHUL BHATNAGAR
Non-Executive - Independent DirectorMr.VAIBHAV KARANDIKAR
Non-Executive - Non Independent DirectorMs.RENEE VISWONATH AMONKAR
Executive DirectorMr.RACHID AYARI
Executive DirectorMr.ERIC MANSION
Non-Executive - Non Independent DirectorMr.Arjun Thakkar
Company Secretary & Compliance OfficerAwards & Recognition
4 Awards- Featured in the ET Best Brands in Healthcare 2024
- Awarded 'Great Place to Work' Certification in India (2024)
- Recognized for ESG and Responsible Business Practices in 2023 CSR Outlook Ratings
- Received India's Best Workplaces in Pharmaceuticals 2023 recognition
Market Information
Company Timeline
68+ Years of Excellence | 8 Major Milestones
Company incorporated as Hoechst Fedco Pharma Private Ltd.
Public offering; listed on Bombay Stock Exchange
Renamed as Hoechst Marion Roussel Ltd following global mergers
Became Aventis Pharma Ltd post-merger of Hoechst and Rhône-Poulenc
Renamed as Sanofi India Ltd to align with parent company
Divested its animal health business
Launched innovative diabetes therapies in India
Expanded digital patient-care platforms and initiatives for non-communicable diseases
The Next Evolution
Contact Information
Registered Office
Sanofi House, 117-B, L&T Business Park, Saki Vihar Road, Powai
Tel: 022-28032000,
Fax: 022-28032939,
Email: igrc.sil@sanofi.com
Website: novartis.com
Corporate Actions
26| Purpose | Ex Date | Record Date | BC Start | BC End |
|---|---|---|---|---|
Final Dividend ₹48 per share | 22 Apr 2026 Wednesday | 22 Apr 2026 Wednesday | - | - |
Interim Dividend ₹75 per share | 07 Nov 2025 Friday | 07 Nov 2025 Friday | - | - |
Final Dividend ₹117 per share | 25 Apr 2025 Friday | 25 Apr 2025 Friday | - | - |
Spin Off | 13 Jun 2024 Thursday | 13 Jun 2024 Thursday | - | - |
Final Dividend ₹117 per share | 03 May 2024 Friday | 03 May 2024 Friday | - | - |
Interim Dividend ₹50 per share | 07 Mar 2024 Thursday | 07 Mar 2024 Thursday | - | - |
Special Dividend ₹183 per share | 28 Apr 2023 Friday | - | 29 Apr 2023 Saturday | 11 May 2023 Thursday |
Final Dividend ₹194 per share | 28 Apr 2023 Friday | - | 29 Apr 2023 Saturday | 11 May 2023 Thursday |
Special Dividend ₹193 per share | 05 Aug 2022 Friday | 08 Aug 2022 Monday | - | - |
Final Dividend ₹181 per share | 12 Apr 2022 Tuesday | - | 16 Apr 2022 Saturday | 26 Apr 2022 Tuesday |
Special Dividend ₹309 per share | 12 Apr 2022 Tuesday | - | 16 Apr 2022 Saturday | 26 Apr 2022 Tuesday |
Final Dividend ₹125 per share | 19 Apr 2021 Monday | - | 21 Apr 2021 Wednesday | 27 Apr 2021 Tuesday |
Special Dividend ₹240 per share | 19 Apr 2021 Monday | - | 21 Apr 2021 Wednesday | 27 Apr 2021 Tuesday |
Final Dividend ₹106 per share | 29 Jun 2020 Monday | - | 01 Jul 2020 Wednesday | 07 Jul 2020 Tuesday |
Special Dividend ₹243 per share | 29 Jun 2020 Monday | - | 01 Jul 2020 Wednesday | 07 Jul 2020 Tuesday |
Final Dividend ₹66 per share | 25 Apr 2019 Thursday | - | 30 Apr 2019 Tuesday | 07 May 2019 Tuesday |
Interim Dividend ₹18 per share | 06 Aug 2018 Monday | 07 Aug 2018 Tuesday | - | - |
Final Dividend ₹53 per share | 26 Apr 2018 Thursday | - | 01 May 2018 Tuesday | 08 May 2018 Tuesday |
Interim Dividend ₹18 per share | 31 Jul 2017 Monday | 01 Aug 2017 Tuesday | - | - |
Final Dividend ₹50 per share | 25 Apr 2017 Tuesday | - | 27 Apr 2017 Thursday | 05 May 2017 Friday |
Interim Dividend ₹18 per share | 04 Aug 2016 Thursday | 05 Aug 2016 Friday | - | - |
Special Dividend ₹22 per share | 13 Apr 2016 Wednesday | - | 19 Apr 2016 Tuesday | 29 Apr 2016 Friday |
Final Dividend ₹25 per share | 13 Apr 2016 Wednesday | - | 19 Apr 2016 Tuesday | 29 Apr 2016 Friday |
Interim Dividend ₹18 per share | 29 Jul 2015 Wednesday | 30 Jul 2015 Thursday | - | - |
Final Dividend ₹24 per share | 16 Apr 2015 Thursday | - | 18 Apr 2015 Saturday | 29 Apr 2015 Wednesday |
Special Dividend ₹11 per share | 16 Apr 2015 Thursday | - | 18 Apr 2015 Saturday | 29 Apr 2015 Wednesday |
₹7,289 Cr.
₹3,165
₹5,189 / 3,054
17.64
₹373.68
8.47
₹179.45
₹10.00
3.89 %
Manage Ratio
FINANCIALS
Cash Flow
Consolidated Figures in Rs. Crores
| Annual Balance Sheet | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Dec 2023 | Dec 2024 | - |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | - | - | - | - | - | - | - | 1,715 | 1,612 | - |
| Equity And Liabilities | - | - | - | - | - | - | - | 1,715 | 1,612 | - |
Shareholding Pattern
Numbers in Percentages
| Quarterly SHP Announcement Date | Mar 2016 12 Apr '16 | Mar 2017 31 Mar '17 | Mar 2018 31 Mar '18 | Mar 2019 18 Apr '19 | Mar 2020 20 Apr '20 | Mar 2021 16 Apr '21 | Mar 2022 12 Apr '22 | Mar 2023 20 Apr '23 | Mar 2024 15 Apr '24 | Mar 2025 19 Apr '25 | Mar 2026 17 Apr '26 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goverments | - | - | - | - | - | - | - | - | - | - | - | - |
| Promoter And Promoter Group | - | - | - | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | - |
| Non Institutions | - | - | - | 10.85% | 10.92% | 10.89% | 11.96% | 13.43% | 10.41% | 11.01% | 12.83% | - |
| FII | - | - | - | - | - | - | - | 6.71% | 6.11% | 5.57% | 5.64% | - |
| DII | - | - | - | - | - | - | - | 19.47% | 23.08% | 23.02% | 21.13% | - |
| Total | - | - | - | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - |
Sanofi India Ltd
Sanofi India Ltd
Sanofi India Ltd is a leading pharmaceutical company and a subsidiary of global healthcare leader Sanofi S. A. Headquartered in Mumbai, Sanofi India operates across the pharmaceutical value chain with a strong presence in manufacturing, marketing, and distribution of prescription medicines.
The company's portfolio encompasses therapeutic segments such as diabetes management, cardiovascular health, central nervous system disorders, and consumer healthcare. Sanofi India maintains a significant investment in research and development, focusing on both innovative branded formulations and legacy products.
With a pan-India reach, Sanofi India serves healthcare professionals, patients, and institutions through an extensive distribution network and established manufacturing facilities in Goa and Ankleshwar. The company is committed to improving access to essential medicines and contributing to public health through various awareness and education initiatives.
Sanofi India Ltd generates revenue primarily through the manufacture and sale of prescription pharmaceuticals and consumer healthcare products. Its business is anchored by strong brands like Lantus (insulin glargine), Allegra (antihistamine), Combiflam, and Amaryl. A significant portion of revenue also comes from contract manufacturing and strategic out-licensing agreements with other healthcare companies.
The company leverages Sanofi's global R&D pipeline and localizes the manufacturing of proven global products for the Indian market.
The growth strategy emphasizes therapeutic leadership in diabetes and cardiology, expansion in over-the-counter (OTC) segments, and increased focus on digital engagement with healthcare professionals. In addition, Sanofi India pursues partnerships with both public and private sectors for broader healthcare access while optimizing operational efficiency through digitization and supply chain initiatives.
Featured in the ET Best Brands in Healthcare 2024
Awarded 'Great Place to Work' Certification in India (2024)
Recognized for ESG and Responsible Business Practices in 2023 CSR Outlook Ratings
Received India's Best Workplaces in Pharmaceuticals 2023 recognition
Company incorporated as Hoechst Fedco Pharma Private Ltd.
Public offering; listed on Bombay Stock Exchange
Renamed as Hoechst Marion Roussel Ltd following global mergers
Became Aventis Pharma Ltd post-merger of Hoechst and Rhône-Poulenc
Renamed as Sanofi India Ltd to align with parent company
Divested its animal health business
Launched innovative diabetes therapies in India
Expanded digital patient-care platforms and initiatives for non-communicable diseases
Peer Comparison
| S.No. | Company Name | CMP (₹) | Market Cap (₹ Cr) | Div Yld (%) | NP Qtr (₹ Cr) | Qtr Profit Var (%) | Sales Qtr (₹ Cr) | Qtr Sales Var (%) | ROCE (%) | ROE (%) | Book Value (₹) | EPS TTM (₹) | TTMPE Ratio (₹) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon
Heatmap View
Premium Feature| Company | CMP (₹) | MCap (₹ Cr) | EPS TTM (₹) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Financial Ratios
Premium Feature| Company Name | P/E (TTM) | EPS (₹) | D/E | NPM | GPM | ROE (%) | ROCE (%) | P/B | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon